https://www.pharmiweb.com/press-release/2022-05-03/horizon-therapeutics-plc-receives-european-commission-ec-approval-of-uplizna-inebilizumab-for-the-treatment-of-adults-with-neuromyelitis-optica-spectrum-disorder-nmosd
0
0
5/3/22 at 9:12am
Organization
PharmiWeb.com
Authors
-- NMOSD is a devastating autoimmune disease of severe and recurrent central nervous system attacks which can result in blindness, paralysis and death ---- UPLIZNA is indicated as monotherapy for treatment of adult patients with NMOSD who are anti-aquaporin-4…
Create an account
or login to join the discussion